Latuda: “Procognitive” or Pro-Profit? Carlat Reports

Latuda: “Procognitive” or Pro-Profit?

The Carlat Psychiatry Report, Volume 9, Number 6, June 2011
https://www.thecarlatreport.com/newsletter-issue/tcprv9n6/

From The Carlat Psychiatry Report, June 2011, Schizophrenia

Issue Links: Learning Objectives | Editorial Information

R. Andrew Sewell, MD

Lurasidone (Latuda) was approved by the FDA for schizophrenia in October 2010 and is the 10th atypical antipsychotic in our toolbox. The key question is: does lurasidone have any advantages over existing agents, or is it just another “me-too” drug?

You can't view details of this content, please login or buy subscription here

R. Andrew Sewell, MD

Associate research scientist, VA Connecticut Healthcare, Yale University School of Medicine

Dr. Sewell has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.